Basit öğe kaydını göster

dc.contributor.authorMüderris, Togay
dc.contributor.authorYar Sağlam, Atiye Seda
dc.contributor.authorÜnsal, Döndü
dc.contributor.authorMülazimoğlu, Selçuk
dc.contributor.authorSevil, Ergün
dc.contributor.authorKayhan, Handan
dc.date.accessioned2022-09-12T10:31:24Z
dc.date.available2022-09-12T10:31:24Z
dc.date.issued2022en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12868/1559
dc.identifier.urihttps://v2.sherpa.ac.uk/id/publication/20441
dc.description.abstractAge‑related hearing loss (ARHL) is a major public health concern, which is characterized by gradual, progres‑ sive sensorineural hearing loss and deterioration of sound localization, with no effective treatment available to date. The aim of the present study was to evaluate the efficacy of resve‑ ratrol to prevent and treat ARHL. For this purpose, 32 male C57BL/6 mice were assigned to four groups: Early treatment, late treatment, control and sham control. The experiment lasted for 15 months. Treatment was started at three months of age in the early treatment group and at sixth months in the late treatment group. The auditory brainstem response test was performed once every three months. At the end of the study period, inducible nitric oxide synthase (iNOS), cyclooxygenase (COX)‑2, NF‑κB, Bcl‑2, Bcl‑xL, Bax, Bcl‑2 homologous antagonist/killer (Bak), caspase‑3 and caspase‑9 levels in the cochlear tissues of the animals were analyzed by reverse transcription‑quantitative PCR. Hearing thresholds of the mice in the early treatment group were better than those in the other groups (P<0.001) at the end of the study. However, hearing levels in the late treatment group were not significantly different from those in the control groups (P>0.05), although mean thresholds were lower. The threshold shift in the early treatment group was significantly lower at all frequencies when compared with those in the control groups (P<0.001). The mRNA expression levels of pro‑apoptotic genes Bax and Bak were lower (P<0.05), anti‑apoptotic genes Bcl‑2 and Bcl‑xL were higher (P<0.05), NF‑κB, COX‑2 and iNOS as genes that have a role in inflammation and caspase‑3 and caspase‑9 as genes with a vital role in apoptosis were lower (P<0.05) in the early treatment group when compared with the late treatment and control groups. These results suggested that resveratrol is effective in the prevention of ARHL, particularly when started prior to the beginning of hearing loss.en_US
dc.language.isoengen_US
dc.relation.isversionof10.3892/etm.2021.10962en_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAge‑related hearing lossen_US
dc.subjectAuditory brainstem responseen_US
dc.subjectResveratrolen_US
dc.subjectOxidative stressen_US
dc.subjectAntioxidantsen_US
dc.titleEfficiency of resveratrol in the prevention and treatment of age-related hearing lossen_US
dc.typearticleen_US
dc.contributor.departmentALKÜ, Fakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümüen_US
dc.identifier.volume23en_US
dc.identifier.issue1en_US
dc.identifier.startpage1en_US
dc.identifier.endpage7en_US
dc.relation.journalExperimental and Therapeutic Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster